Shares of iBio, Inc. (NYSEMKT:IBIO – Get Free Report) fell 3.2% on Thursday . The stock traded as low as $1.82 and last traded at $1.84. 100,619 shares changed hands during trading, a decline of 11% from the average session volume of 113,212 shares. The stock had previously closed at $1.90.
iBio Stock Performance
The company’s 50-day moving average is $1.83. The company has a debt-to-equity ratio of 0.04, a current ratio of 0.91 and a quick ratio of 0.91.
iBio Company Profile
iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.
See Also
- Five stocks we like better than iBio
- What is Insider Trading? What You Can Learn from Insider Trading
- Roblox: The Bottom Just Fell Out of the Metaverse
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Airbnb Stock Plummets After Earnings, But is It a Buy?
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Uber’s Earnings Drop Is Investors Opportunity
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
